Greg Verdine is the Erving Professor of Chemistry at Harvard University, and is a Venture Partner at Third Rock Ventures. His research effort aims to (i) discover entirely new molecular classes of drugs to tackle so-called “undruggable” targets; and (ii) understand fundamental aspects of DNA damage recognition and repair.
« Go Back